Abstract:Abstract BACKGROUND As the global prevalence of inflammatory bowel disease (IBD) rises, it is important that the direst costs associated with medical care be analyzed to determine the impact on healthcare systems. Components making up the direct healthcare cost to the IBD population (e.g., hospitalizations, colonoscopies, and medications) are constantly changing and with this so may be the cost related to taking care of the IBD population. AIM Analyze component-specific costs, total costs, and the proportion of total costs attributed to each component, and changes over time. METHODS Using a validated algorithm and population-based administrative data from Alberta, Canada (Population: 4.3m), prevalent IBD patients were identified from fiscal year (FY) 2009/10 to 2018/19 (April 1–March 31). Costs from the Discharge Abstract Database, Physician Claims, National Ambulatory Care, and Pharmacy Information Network were converted to 2020 (CAD$) costs using Statistics Canada’s Consumer Price Index. Only IBD-related outpatient dispensed medications were included in the costs (inpatient not captured in data). Annual average costs per patient (with 95% confidence interval [CI]) were calculated. Medication costs per person were stratified on whether or not an individual was on a biologic (e.g. anti-TNF therapy) versus a non-biologic IBD-related medication (e.g., 5-ASA). The cost of an individual’s IBD-related hospitalization, IBD-related surgery, emergency department visit, colonoscopy, or IBD-related medication were calculated. Proportion of the total costs contributed by each category were calculated. Temporal trends of mean annual costs were analyzed using Poisson, or negative binomial, regression and average annual percentage change (AAPC) with 95%CI were reported. RESULTS In FY2018/19, the average cost of an IBD patient was $15,786 (95%CI:15,478, 16,094). This cost significantly increased from the 2009 value ($8,477; 95%CI: 8,407, 8,908) with an AAPC of 6.28% (95%CI: 5.51, 7.05). The annual costs of medications when a patient is on one or more biologics significantly increased (AAPC: 3.48%; 95%CI:2.32, 4.65). In contrast, the average annual cost per patient of IBD-related non-biologic medications significantly decreased (AAPC: -2.32; 95%CI: -3.48, -1.14). The largest contributor to IBD costs is medications (57.6% of the total costs) followed by IBD-related hospitalizations (20.6%). The costs of IBD-related hospitalizations and surgeries have remained stable, whereas the costs for emergency department visits and colonoscopies increased. DISCUSSION The costs associated with treating people IBD is rising and predominantly attributable to the cost of biologics. As the prevalence of IBD continues to increase, healthcare systems, payers and governments need to work to address these costs while ensuring these individuals receive the care they need. *Proportions will not add up to 100% as individuals can be captured in multiple cost categories each year (e.g., an IBD-related surgery cost is also captured as a hospitalization) and not all costs are reported in table. Overall and Biologics are Per Person; Hospitalization and Sugery are Per Event

Su1301 Incidence and Phenotype of Inflammatory Bowel Disease from 2012-2013 Across 9 Countries in Asia: Results from the 2012 Access Inception Cohort

IDDF2018-ABS-0223 an Eastern Chinese Multicenter Survey on Health-Related Quality of Life in Inflammatory Bowel Disease Patients and Disease-Related Perception of Caregivers

Economic Burden and Health Care Access for Patients with Inflammatory Bowel Diseases in China: Web-Based Survey Study

P1188 Epidemiology and direct healthcare costs of patients with Inflammatory Bowel Disease (IBD) in an Asian cohort in the first year following diagnosis

1012 Natural History of Inflammatory Bowel Disease in Asia: A Follow-Up Population-Based Cohort Study

Early Course of Inflammatory Bowel Disease in a Population-Based Inception Cohort Study From 8 Countries in Asia and Australia

Incidence and Phenotype of Inflammatory Bowel Disease Based on Results from the Asia-pacific Crohn's and Colitis Epidemiology Study.

78 Incidence and Phenotype of Inflammatory Bowel Disease from 13 Countries in Asia-Pacific: Results from the Asia-Pacific Crohn's and Colitis Epidemiologic Study 2011-2013

Epidemiology of Inflammatory Bowel Disease from 1981 to 2014: Results from a Territory-Wide Population-Based Registry in Hong Kong.

High Incidence and Morbidity of Clostridium Difficile Infection among Hospitalized Patients with Inflammatory Bowel Disease: A Prospective Observational Cohort Study

THE COST OF INFLAMMATORY BOWEL DISEASE: A POPULATION-BASED ANALYSIS OF ADMINISTRATIVE DATA

The hospitalization burden of inflammatory bowel disease in China: a nationwide study from 2013 to 2018

P1156 Characteristics and outcomes of over a million Inflammatory Bowel Disease patients in seven countries: a multinational cohort study

The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology Commission

Clinical Presentation of Inflammatory Bowel Disease： a Hospital Based Retrospective Study of 379 Patients in Eastern China

Disease Burden of Inflammatory Bowel Disease in China from 1990 to 2019 and Its Predictions

Trends and Factors Associated with Hospitalization Costs for Inflammatory Bowel Disease in the United States

Quality of life of inflammatory bowel disease at diagnosis in 8 countries in Asia: The ACCESS study

Clinical Characteristics of 379 Patients with Inflammatory Bowel Disease

Incidence of inflammatory bowel disease in Asia-Pacific: First results from the Asia-Pacific epidemiology Crohn's and colitis (ACCESS) study

Trends and Factors Affecting Hospitalization Costs in Patients with Inflammatory Bowel Disease: A Two-Center Study over the Past Decade.